Redox status of plasma homocysteine and other plasma thiols in stroke patients

Atherosclerosis

Volumn 151, Issue 2, 2000, Pages 535-539

  Andersson, A ^a   Hultberg, B ^a   Lindgren, A ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cysteine; Glutathione; Homocysteine; Plasma; Redox status; Stroke patients

Indexed keywords

CYSTEINE; GLUTATHIONE; HOMOCYSTEINE; THIOL;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HUMAN; MALE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR; STROKE;

AGED; CEREBROVASCULAR ACCIDENT; CYSTEINE; FEMALE; GLUTATHIONE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; OXIDATION-REDUCTION; REFERENCE VALUES; SULFHYDRYL COMPOUNDS;

EID: 0033865141     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00418-9     Document Type: Article

References (22)

1. Mudd S.H., Levy H.L., Skovby F. Disorders of transsulfuration. Scriver C.G., Beaudet A.L., Sly W.S., Valle D. The Metabolic Basis of Inherited Disease. 6th ed. 1989;693-734 McGraw-Hill, New York.
2. Brattström L., Hardebo J., Hultberg B. Moderate homocysteinemia - a possible risk factor for arteriosclerotic cerebrovascular disease. Stroke. 15:1984;1012-1016.
3. Boers G.H.J., Smals A.G.H., Trijbels F.J.M., Fowler B., Bakkeren J.A.J.M., Schoonderwaldt H.C., Kleijer W.J., Kloppenborg P.W.C. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N. Engl. J. Med. 313:1985;709-715.
4. Clarke R., Leslie D., Robinson K., Naughten E., Cahalane S., Fowler B., Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N. Engl. J. Med. 324:1991;1149-1155.
5. Stampfer M.J., Malinow M.R., Willet W.C., Newcomer L.M., Upson B., Ullman D., Tishler P.V., Henneken C.H. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. J. Am. Med. Assoc. 268:1992;877-881.
6. Boushey C.J., Beresford S.A.A., Omen G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J. Am. Med. Assoc. 274:1995;1049-1056.
7. Refsum H., Ueland P.M., Nygård O., Vollset S.E. Homocysteine and cardiovascular disease. Annu. Rev. Med. 49:1998;31-62.
8. Mansoor M.A., Svardal A.M., Ueland P.M. Determination of in vivo redox status of cysteine, cysteinylglycine, homocysteine and glutathione in human plasma. Anal. Biochem. 200:1992;218-229.
9. Andersson A., Lindgren A., Hultberg B. Effect of thiol oxidation and thiol export from erythrocytes on determination of redox status of homocysteine and other thiols in plasma from healthy subjects and patients with cerebral infarction. Clin. Chem. 41:1995;361-366.
10. Ueland P.M. Homocysteine species as components of plasma redox thiol status. Clin. Chem. 41:1995;340-342.
11. Meister A. Glutathione metabolism and its selective modification. J. Biol. Chem. 263:1988;17205-17208.
12. Bannai S., Tateishi N. Role of membrane transport in metabolism and function of glutathione in mammals. J. Membr. Biol. 89:1986;1-8.
13. Kretzschmar M. Regulation of hepatic glutathione metabolism and its role in hepatotoxicity. Exp. Toxicol. Pathol. 48:1996;439-446.
14. Aebi S., Assereto R., Lauterburg B.H. High-dose intravenous glutathione in man. Pharmacokinetics and effects on cysteine in plasma and urine. Eur. J. Clin. Invest. 21:1991;103-110.
15. Halliwell B., Gutteridge J.M.C. The antioxidants of human extracellular fluids. Arch. Biochem. Biophys. 280:1990;1-8.
16. Hultberg B., Andersson A., Arnadottir M. Reduced, free and total fractions of homocysteine and other thiol compounds in plasma from patients with renal failure. Nephron. 70:1995;62-67.
17. Andersson A., Lindgren A., Arnadottir M., Prytz H., Hultberg B. Thiols as a measure of plasma redox status in healthy subjects and in patients with renal or liver failure. Clin. Chem. 45:1999;1084-1086.
18. Andersson A., Isaksson A., Brattström L., Hultberg B. Homocysteine and other thiols determined in plasma by HPLC and thiol specific postcolumn derivatization. Clin. Chem. 39:1993;1590-1597.
19. Mansoor M.A., Bergmark C., Svardal A.M., Lönning P.E., Ueland P.M. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with early-onset peripheral vascular disease. Arterioscler. Thromb. Vasc. Biol. 15:1995;232-240.
20. Hultberg B., Andersson A., Masson P., Larson M., Tunek A. Plasma homocysteine and thiol compound fractions after oral administration of N-acetylcysteine. Scand. J. Clin. Lab. Invest. 54:1994;417-422.
21. Guttormsen A.B., Svarstad E., Ueland P.M., Refsum H. Elimination of homocysteine from plasma on subjects with end-stage renal failure. Kidney Int. 52:1997;495-502.
22. Witzum J.L. The oxidation hypothesis of atherosclerosis. Lancet. 344:1994;793-795.